Qianjin Pharmaceutical (600479.SH) and its subsidiaries obtained drug registration certificates

Zhitong Finance App News, Qianjin Pharmaceutical (600479.SH) issued an announcement. Recently, the company and its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. (“Qianjin Xiangjiang Pharmaceutical” for short) received “Drug Registration Certificates” for didroprogesterone tablets, baritinib tablets (4 mg, 2 mg) and dagliflozin tablets (5 mg, 10 mg), and dagliflozin tablets (5 mg, 10 mg), respectively, approved and issued by the State Drug Administration.

Diloprogesterone tablets, baritinib tablets, and dapagliflozin tablets have obtained drug registration certificates, which is considered to have passed the consistency evaluation, further enriching the company's product pipeline and contributing to the company's sustainable development.